High cost oncology drugs have become the pharmaceutical industry’s new blockbusters, accounting for more than a quarter of companies’ revenue despite being for relatively niche indications. Over the last decade the annual revenue generated from cancer drugs by the top 10 pharma companies has increased by 70%, according to a review published in Cancer journal. ...
Oncology drugs have become the new industry blockbusters
14 Oct 2021